Cediranib
ASCO: Olaparib and cediranib combo promising for recurrent ovarian cancer
June 05, 2014For women with recurrent platinum-sensitive ovarian cancer, the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib is more effective than olaparib alone.
Cediranib improves survival in recurrent ovarian cancer
October 21, 2013Women with ovarian cancer that has recurred after chemotherapy survived longer after treatment with cediranib, a biological therapy, according to research.
Sign Up for Free e-newsletters
ONA Articles
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Recommended Therapies for Polycythemia Vera Underused
- PFS, OS Improved With Sequential Rituximab/Bendamustine, Rituximab/Cytarabine in Untreated Mantle Cell Lymphoma
- Stringent Complete Response Criteria for Patients With Multiple Myeloma May Lack Predictive Value
- ADT May Up Risk for Heart Failure in Prostate Cancer Patients
- Smartphone App Improves Management of Cancer-Related Pain, Anxiety
- Counseling Patients on Oral Chemotherapy
- Proscription on Antiperspirant Use During Radiotherapy: Does the Advice Still Apply?
- Lung Cancer-Specific Distress Screening Tool Not Needed But Has Potential Benefit
- Prophylaxis Improves Postchemotherapy Nausea/Vomiting Frequency, Hospitalizations
- Steering Patients Toward Reliable Internet Resources
- Postmastectomy Breast Reconstruction Safe in Older Women With Breast Cancer
- CIPN in Breast Cancer: Do Subjective and Objective Measures Correlate?
- Risk of Breast Cancer Higher for African American Female Veterans
- Patients, Physicians Do Not Recognize Fatigue the Same
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
| Bone Cancer | Regimens | Drugs |
| Brain Cancer | Regimens | Drugs |
| Breast Cancer | Regimens | Drugs |
| Endocrine Cancer | Regimens | Drugs |
| Gastrointestinal Cancer | Regimens | Drugs |
| Genitourinary Cancer | Regimens | Drugs |
| Gynecologic Cancer | Regimens | Drugs |
| Head and Neck Cancer | Regimens | Drugs |
| Hematologic Cancer | Regimens | Drugs |
| Lung Cancer | Regimens | Drugs |
| Other Cancers | Regimens | |
| Rare Cancers | Regimens | |
| Skin Cancer | Regimens | Drugs |